Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

Abstract

Co-therapy for the treatment of neurological dysfunctions comprising administration of one or more fructopyranose sulfamates and erythropoietin.

1 . A method for treating a neurological dysfunction in a subject in need thereof, comprising co-therapy with a therapeutically effective amount of a fructopyranose sulfamate and erythropoietin; wherein the amount of the fructopyranose sulfamate and the amount of the erythropoietin are selected to produce a synergistic effect.  
   
   
       2 . The method of  claim 1  wherein the fructopyranose sulfamate is topiramate.  
   
   
       3 . The method of  claim 1 , wherein the therapeutically effective amount of the fructopyranose sulfamate is from about 10 to 1000 mg.  
   
   
       4 . The method of  claim 1 , wherein the erythropoietin is epoetin alfa.  
   
   
       5 . The method of  claim 1 , wherein the therapeutically effective amount of erythropoietin is from about 1 to 15000 I.U./kg.  
   
   
       6 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of acute neurodegenerative disorders and chronic neurodegenerative disorders.  
   
   
       7 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of cerebrovascular insufficiency, focal brain trauma, diffuse brain trauma, spinal cord injury, cerebral ischemia, cerebral infarction, embolic occlusion, thrombotic occlusion, reperfusion following acute ischemia, perinatal hypoxic-ischemic injury, cardiac arrest, intracranial hemorrhage and whiplash shaken infant syndrome.  
   
   
       8 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multi-system degeneration (Shy-Drager syndrome), chronic epileptic conditions associated with neurodegeneration, motor neuron diseases, amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease/spinocerebellar ataxia type 3 degeneration, olivopontocerebellar degeneration, Gilles De La Tourette's disease, bulbar palsy, pseudobulbar palsy, spinal muscular atrophy, spinobulbar muscular atrophy (Kennedy's disease), multiple sclerosis, primary lateral sclerosis, familial spastic paraplegia, Werdnig-Hoffmann disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease, Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, familial dysautonomia (Riley-Day syndrome), prion disease, Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, Kuru insomnia and fatal familial insomnia.  
   
   
       9 . The method of  claim 8 , wherein the neurological dysfunction is selected from a group consisting of Alzheimer's disease and Parkinson's disease.  
   
   
       10 . The method of  claim 1 , wherein the neurological dysfunction is dementia.  
   
   
       11 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of diminished memory, diminished mental capacity and mental deterioration.  
   
   
       12 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of neurological and psychiatric manifestations associated with disease or injury.  
   
   
       13 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of psychiatric and neurological manifestations associated with peripheral disease.  
   
   
       14 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of plexopathies, neuropathies, and disorders of the cranial nerves.  
   
   
       15 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of psychiatric and neurological manifestations associated with an acute neurodegenerative disorder.  
   
   
       16 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of psychiatric and neurological manifestations associated with a chronic neurodegenerative disorder.  
   
   
       17 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of psychiatric and neurological manifestations resulting from an epileptic condition.  
   
   
       18 . The method of  claim 1 , wherein the neurological dysfunction is selected from a group consisting of psychiatric and neurological manifestations of a post-ictal, a post-seizure or an inter-ictal state.  
   
   
       19 . The method of  claim 1 , wherein the fructopyranose sulfamate is topiramate and the erythropoietin is epoetin alfa.  
   
   
       20 - 24 . (canceled)